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Recently, Sonkar and colleagues pub-
lished a comprehensive review about the 
glycerophosphocholine (GPC) pathway and 
its role in cancer biology (Sonkar et al., 2019). 
The authors address the enzymes of the GPC 
breakdown pathway; the oncogenic signaling 
pathways and transcription factors that regu-
late the GPC pathway; the interactions of the 
GPC pathway with other biochemical path-
ways such as glycolysis and triglyceride me-
tabolism, and finally focus on non-invasive 
magnetic resonance spectroscopy techniques 
for detection of GPC in tumor tissue. Activa-
tion of choline metabolism is a critical step of 
cancer development and may lead to in-
creased levels of phosphocholine, GPC and 
total choline-containing compounds (Hana-
han and Weinberg, 2011; Griffiths et al., 
1981; Daly et al., 1987; Aboagye and Bhu-
jwalla, 1999; Gillies et al., 2002). These 
changes can be detected by magnetic reso-
nance spectroscopy (Baek et al., 2008; Bolan 
et al., 2003; He et al., 2003-2004; Al-Saffar et 
al., 2017; Glunde et al., 2011). The glycer-
ophosphodiesterase GPCPD1 is a key enzyme 
in choline metabolism that cleaves GPC to 
glycerol-3-phosphate (G3P) and choline 
(Stewart et al., 2012). This activity mediates 
integrin expression, tumor cell adhesion, 
spreading and migration (Lesjak et al., 2014; 
Marchan et al., 2012). Recently, glycerol-3-
phosphate acyltransferase1, which further 
processes G3P to generate lysophosphatidic 
acid (LPA) has been shown to promote tumor 
cell migration and is associated with poor sur-
vival in ovarian cancer (Marchan et al., 2017).  
Besides phospholipid metabolism and 
metastasis tumor progression involves nu-
merous further processes, such as prolifera-
tion (Schmidt et al., 2008; Hellwig et al., 
2016; Siggelkow et al., 2012), immune cell 
infiltration (Edlund et al., 2019; Schmidt et 
al., 2012, 2018; Godoy et al., 2014), oxidative 
stress response (Cadenas et al., 2019; 2014; 
2012). Studies in future will have to show if 
targeting members of the glycerophospho-
choline pathway will delay tumor progres-
sion. The present review of Sonkar et al. gives 
a comprehensive summary of the state-of-the-
art in this field and is of high value to anyone 
interested in how choline-phospholipid-me-
tabolism is linked to tumor development.  
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